Pharmaceuticals & Biotech

ClearLake Labs Expands Premium Research Peptide Access Across North America with Verified Third-Party Testing

ClearLake Labs has emerged as a trusted peptide supplier for buying peptides online. ClearLake Labs, an emerging leader and rapidly expanding peptide supplier, today announced the expansion of its premium research peptide access across the United States, Canada, and Costa … Continue reading →

PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “PI3K Inhibitor Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in PI3K Inhibitor pipeline landscape. It covers the PI3K Inhibitor pipeline drug profiles, including PI3K Inhibitor clinical and nonclinical stage products. It also … Continue reading →

ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “ALK Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

SYK Inhibitors Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical … Continue reading →

PARP Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “PARP inhibitor Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the PARP inhibitor pipeline landscape. It covers the PARP inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

NLRP3 Protein Inhibitors Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “NLRP3 Protein Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape. It covers the NLRP3 Protein Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Fibrodysplasia Ossificans Progressiva Market Outlook 2032: Rising Prevalence and Innovative Pipeline Therapies Drive Growth, analyses DelveInsight

Fibrodysplasia Ossificans Progressiva Market The Fibrodysplasia Ossificans Progressiva (FOP) market is projected to witness substantial growth during the forecast period, primarily driven by increasing disease awareness and improving diagnosis rates. In addition, the introduction of multiple pipeline therapies across various … Continue reading →

Lupus Nephritis Market to Surpass USD 1.8 Billion by 2034 | 20+ Companies and Emerging Therapies Driving Growth, analyses DelveInsight

Lupus Nephritis Market Prominent Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, … Continue reading →

Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight

Metastatic Triple-Negative Breast Cancer Market Leading Metastatic Triple-Negative Breast Cancer companies include AstraZeneca, Takeda, Novartis, Roche, Eli Lilly, Merck, Bristol-Myers Squibb, Gilead Sciences, and others. DelveInsight’s report, “Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size, and Market Forecast … Continue reading →

PARP Inhibitor Clinical Pipeline Demonstrates Strong Momentum with 30+ Companies Advancing Innovative Therapies | DelveInsight

PARP Inhibitor Pipeline Insight Leading PARP Inhibitor companies driving innovation in this space include TESARO, AstraZeneca, Sun BioPharma, Eisai Co., BeiGene, IMPACT Therapeutics, and Ribon Therapeutics, among others. DelveInsight’s “PARP Inhibitor Pipeline Insights 2026” report delivers a comprehensive overview of … Continue reading →

Friday - March 27, 2026

Category Archives: Pharmaceuticals & Biotech